1 study found for:    23863050 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Conditions: Hormone Refractory Prostate Cancer;   Bone Metastases
Interventions: Drug: Radium-223 dichloride (Xofigo, BAY88-8223);   Drug: Placebo;   Drug: Best standard of care (BSoC)

Indicates status has not been verified in more than two years